CD44 and prostate carcinoma: Although several articles agreed on the fact that a loss of CD44 expression during human prostate cancer progression correlated with higher tumor grade and distant metastasis, recently CD44v6 [28] and v10 [29] have been proposed as useful biomarkers predicting poor outcome following radical prostatectomy for localized PCa.